| Anacetrapib , a cholesteryl ester transfer protein inhibitor. | |
| | |
MedLine Citation:
|
PMID: 22191425 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Introduction: Inhibition of cholesteryl ester transfer protein (CETP) has the ability to increase high-density lipoprotein (HDL)-cholesterol levels and potentially reduce cardiovascular risk. The first CETP inhibitor, torcetrapib, was discontinued due to off-target effects resulting in increased mortality. However, anacetrapib does not appear to exhibit these effects and is being developed as a selective inhibitor of CETP to be orally administered for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. Areas covered: Areas covered are: mode of action, preclinical development and clinical trials of anacetrapib, a CETP inhibitor. The article provides an understanding of the pharmacokinetic and pharmacodynamic characteristics of anacetrapib and insight into its clinical efficacy and safety. In clinical trials, anacetrapib produced dose-dependent elevations in HDL-cholesterol and reductions in low-density lipoprotein (LDL)-cholesterol. Furthermore, anacetrapib has been shown to increase apolipoprotein (apo) A-I and decrease apoB levels. Expert opinion: Anacetrapib is a potent, reversible CETP inhibitor that is not only able to increase HDL-cholesterol, but also further decrease LDL-cholesterol when taken in combination with a statin. Safety and tolerability studies reported to date are promising. The results from Phase III trials investigating the efficacy of anacetrapib for the prevention of major coronary events in patients with atherosclerotic cardiovascular disorders are awaited with interest. |
| | |
Authors:
|
Amanda J Hooper; John R Burnett |
Related Documents
:
|
15681125 - Abuse pattern of gestational toluene exposure and early postnatal development in rats. 6293445 - Pathologic effects of 2,2',4,4',5,5'-and 2,3',4,4',5,5'-hexabromobiphenyl in white legh... 1556385 - Use of hair analysis for evaluating mercury intoxication of the human body: a review. 3398075 - Female reproduction and pup survival and growth for mice fed a cadmium-containing purif... 8257395 - Cerebral encephalomalacia in commercial turkeys. 729515 - Elastase-inhibitory activity of aortic glycosaminoglycans during cholesterol-induced at... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-22 |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: - ISSN: 1744-7658 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Royal Perth Hospital, Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA , Perth , Western Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Electricity production from anaerobic digestion of household organic waste in Ontario: Techno-econom...
Next Document: Acute and long-term estradiol kinetics in smoking postmenopausal women.